ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Viral therapy"

  • 2020 American Transplant Congress

    Utilization of Organs from Donors Exposed to Hepatitis C: ? Standard of Care

    M. Marvin1, S. Gaines2, P. Mohan3, A. Kotru1, C. Koo1, B. Addissie4, A. Unzueta4, S. Khurana4

    1Transplantation and Liver Surgery, Geisinger, Danville, PA, 2Pharmacy, Geisinger, Danville, PA, 3Nephrology, Geisinger, Danville, PA, 4Hepatology, Geisinger, Danville, PA

    *Purpose: To report the results of a clinical program to utilize livers and kidneys from donors exposed to Hepatitis C.*Methods: We initially started to explore…
  • 2020 American Transplant Congress

    Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors

    N. Terrault1, J. Burton2, E. Verna3, C. Mobley4, D. Victor4, J. Trotter5, C. Niemann6, R. Rubin7

    1University of Southern California, Los Angeles, CA, 2UC, Denver, CO, 3Columbia Universeity, New York, NY, 4Houston Methodist, Houston, TX, 5Baylor University, Dallas, TX, 6UCSF, San Francisco, CA, 7Piedmont Atlanta Hosptial, Atlanta, GA

    *Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…
  • 2020 American Transplant Congress

    Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus

    H. Joharji, D. Alkortas, A. Ajlan, E. Devol, M. Ahmed, F. Aba Al-Khail, H. Elsiesy, M. Alsebayel, H. Alashgar, M. Alquaiz, W. Alhamoudi, A. Almoshishir, A. Aljedai

    King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

    *Purpose: Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of HCV has shifted in the last few…
  • 2020 American Transplant Congress

    Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients

    M. Chunduru, K. Schnelle, H. Winters, O. Witkowsky, L. Von Stein

    The Ohio State Wexner Medical Center, Columbus, OH

    *Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…
  • 2020 American Transplant Congress

    Association between Ezetimibe Usage and Hepatitis C RNA Levels in Uninfected Kidney Transplant Recipients Who Received Hepatitis C Infected Kidneys

    A. Azhar, M. Yazawa, M. Talwar, V. Balaraman, A. Bhalla, U. A. Agbim, B. Maliakkal, J. P. Kothadia, S. Nair, J. D. Eason, M. Z. Molnar

    James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN

    *Purpose: Our previous data showed that transplantation of kidneys from hepatitis C virus (HCV) infected donors to HCV negative recipients achieved excellent short-term graft function,…
  • 2020 American Transplant Congress

    Single Center Experience of Valganciclovir and Adjunctive CMV IVIG for the Treatment of CMV Infection in Lung Transplant Recipients

    A. A. Fernandez1, N. Sinha2, M. Loebe2, J. Glaze2, S. Manickavel2, M. Fernandez2, T. Pastrana2, J. Simkins3, J. Camargo3, M. I. Morris3, L. Abbo3, Y. Natori3

    1Infectious Disease, University of Miami Jackson Memorial Hospital, Miami, FL, 2University of Miami Jackson Memorial Hospital, Miami, FL, 3Transplant Infectious Disease, University of Miami Jackson Memorial Hospital, Miami, FL

    *Purpose: Cytomegalovirus(CMV) infection happens commonly and causes significant morbidity in lung transplant (LTx) recipients. The use of CMV hyperimmune globulin (CMVIg) as an adjunctive treatment…
  • 2019 American Transplant Congress

    Burden of Respiratory Syncytial Disease among Hospitalized Immunocompromised Adults

    H. Nam, M. Ison

    Northwestern University Comprehensive Transplant Center, Chicago, IL

    *Purpose: Respiratory syncytial virus (RSV) is associated with significant mortality amongst hematopoietic stem cell transplant (HSCT) and lung transplant recipients. Although RSV is responsible for…
  • 2019 American Transplant Congress

    A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 is Safe and Immunogenic in Healthy Volunteers and Entering a Phase 2 Trial in Kidney Transplant Recipients

    C. N. Kotton1, M. Schwendinger2, G. Thiry3, B. De Vos4, F. De Boever5, G. Leroux-Roels6, A. Lilja7

    1Infectious Diseases Division, Boston, MA, 2Hookipa Biotech AG, Vienna, Austria, 3Hookipa Biotech GmbH, VIenna, Austria, 4Bejamad sprl/bvba, Beersel, Belgium, 5Centrum voor vaccinologie (CEVAC), Gdent, Belgium, 6Centrum voor vaccinologie (CEVAC), Gent, Belgium, 7Hookipa Biotech GmbH, Vienna, Austria

    *Purpose: Cytomegalovirus (CMV) is a significant pathogen in pregnancy and immunocompromised patients. Antiviral prophylaxis is limited by toxicities, recurrent infection, and resistance. A safe and…
  • 2019 American Transplant Congress

    Reduction in Waitlist Time Using HCV Positive Liver Grafts in HCV Negative Recipients

    E. M. Bugeaud, N. Bzowej, J. Hand, J. Scheuermann, H. Bohorquez, C. Brown, D. Bruce, I. Carmody, A. Cohen, S. Joshi, N. Latt, J. Seal, D. Sonnier, G. Therapondos, G. Tyson, N. Girgrah, G. Loss

    Ochsner Health System, New Orleans, LA

    *Purpose: With direct-acting antiviral (DAA) therapy, we feel that HCV+ organs are safe for all patients regardless of their HCV status and have adopted a…
  • 2019 American Transplant Congress

    Early Achievement of Sustained Virological Response in Liver Transplant Recipients with Hepatitis C Reduces Risks of End Stage Renal Disease

    M. Yoshikawa1, T. Fukumoto2

    1Nephrology, Kobe University Hospital, Kobe, Japan, 2Hepato-Biliary-Pancreas Surgery, Kobe University Hospital, Kobe, Japan

    *Purpose: Chronic kidney disease (CKD) is common after liver transplantation (LT) and result worse morbidity and mortality. Hepatitis C virus (HCV) infection is recognized as…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences